
|Videos|May 5, 2014
The Impact of FLT3 Inhibitors for the Treatment of AML
Author(s)Meir Wetzler, MD
Meir Wetzler, MD, from Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.
Advertisement
Clinical Pearls
Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.
- In CML, initially only imatinib was available in the frontline, but now nilotinib and dasatinib are approved.
- FLT3 inhibitors did not show significant efficacy in the relapsed/refractory setting of AML, so they were evaluated in the frontline.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































